美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

Urovant Sciences Ltd.

16.24

0.0000

成交量：- -

成交额：- -

市值：5.32亿

市盈率：-3.09

高：16.24

开：16.24

低：16.24

收：16.24

52周最高：16.26

52周最低：7.15

股本：3,274.34万

流通股本：661.20万

量比：- -

换手率：- -

股息：- -

股息率：- -

每股收益(TTM):-5.2539

每股收益(LYR):-4.8245

净资产收益率：218.18%

总资产收益率：-75.13%

市净率：-3.65

市盈率(LYR):-3.37

数据加载中...

总览公司新闻资讯公告

公司资料

公司名字：

Urovant Sciences Ltd.

交易所：

NASDAQ

成立时间：

- -

员工人数：

- -

公司地址：

- -

官网：

http://www.urovant.com

邮编：

- -

电话：

- -

传真：

- -

简介：

Urovant Sciences Ltd.是一家根据百慕达法律于2016年1月27日以Roivant PPS Holdings Ltd.名义注册成立的豁免有限公司。公司于2016年11月14日更名为Thalavant Sciences Ltd.并向Urovant Sciences Ltd.出售。Urovant Sciences是一家临床阶段的生物制药公司，致力于为泌尿系统疾病开发和商业化创新疗法。他们的候选产品vibegron是一种口服，每日一次的小分子，根据体外数据，是一种有效且高度选择性的β-3激动剂。Vibegron目前正在开发用于三种潜在适应症：膀胱过度活动症（OAB），良性前列腺增生或BPH男性的OAB治疗以及肠易激综合症或IBS引起的腹痛治疗。该公司的第二个候选产品URO-902是一种新型基因疗法，是该公司正在为口服药物治疗失败的OAB患者开发的一种新型基因疗法。

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券 | 轻松买卖美股港股A股/美债/ETF/Crypto/期权期货","description":"老虎证券提供多项优惠：港股&Crypto 0佣、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投，免费实时行情与多种工具，立即开户享更多优惠！","keywords":"老虎证券,老虎证券开户,老虎证券香港,老虎证券登录,老虎证券官网,香港证券开户,证券公司开户,股票开户,香港证券公司,香港证券,证券公司,股票投资,投资app,投资平台,股票买卖,股票交易平台,股票app,证券app,新手投资","social":{"ogDescription":"老虎证券提供多项优惠：港股&Crypto 0佣、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投，免费实时行情与多种工具，立即开户享更多优惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/UROV/company"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"UROV","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"UROV\",,,,,undefined,":{"symbol":"UROV","market":"US","secType":"STK","nameCN":"Urovant Sciences Ltd.","latestPrice":16.24,"timestamp":1616788800000,"preClose":16.24,"halted":3,"volume":0,"delay":0,"changeRate":0,"floatShares":6612018,"shares":32743396,"eps":-5.253893,"marketStatus":"停牌","change":0,"latestTime":"03-26 16:00:00 EDT","open":16.24,"high":16.24,"low":16.24,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-5.253893,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1774512000000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":1538020800000,"exchange":"NASDAQ","adjPreClose":16.24,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"UROV\",,,,,undefined,":{"symbol":"UROV","floatShares":6612018,"roa":"-75.13%","roe":"218.18%","lyrEps":-4.824497,"shares":32743396,"dividePrice":0,"high":16.24,"amplitude":0,"preClose":16.24,"low":16.24,"week52Low":7.15,"pbRate":"-3.65","week52High":16.26,"institutionHeld":0,"latestPrice":16.24,"eps":-5.253893,"divideRate":0,"volume":0,"delay":0,"ttmEps":-5.253893,"open":16.24,"prevYearClose":16.13},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/UROV\",params:#limit:5,,,undefined,":[{"market":"US","date":"2021-03-30","symbol":"UROV","reason":null,"defaultRemindTime":1617111000000,"announcedDate":"2021-03-26","type":"delisting","dateTimestamp":1617076800000},{"market":"US","date":"2021-02-12","symbol":"UROV","fiscalQuarterEnding":"2020/12","expectedEps":-1.59,"name":null,"time":"","type":"earning","dateTimestamp":1613106000000,"reportTimeType":"","actualEps":-1.46},{"date":"2020-11-02","symbol":"UROV","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2020/09","expectedEps":-1.5,"defaultRemindTime":1604350800000,"name":null,"time":"盘后","dateTimestamp":1604293200000,"actualEps":null},{"date":"2020-08-13","symbol":"UROV","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2020/06","expectedEps":-1.36,"defaultRemindTime":1597348800000,"name":null,"time":"盘后","dateTimestamp":1597291200000,"actualEps":null},{"date":"2020-06-18","symbol":"UROV","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2020/03","expectedEps":-1.25,"defaultRemindTime":1592510400000,"name":null,"time":"盘后","dateTimestamp":1592452800000,"actualEps":-0.96}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"UROV\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"UROV\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/UROV\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"UROV","date":"2021-03-26","current":-3.091041,"percent":0.6094,"low":-15.852864,"twenty":-8.940566,"median":-4.197764,"eighty":-2.174234,"high":-1.487225,"avg":-5.440772,"sd":3.662094,"marketCap":531425317},"quantilePoints":[{"date":"2021-03-26","current":-3.246198,"twenty":-8.940566,"median":-4.197764,"eighty":-2.174234,"marketCap":531425317}],"updateTime":1774457973347},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.urovant.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":-0.0263},{"period":"1month","weight":-0.0526},{"period":"3month","weight":-0.0539},{"period":"6month","weight":-0.0074},{"period":"1year","weight":0.1378},{"period":"ytd","weight":-0.0421}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Urovant Sciences Ltd.是一家根据百慕达法律于2016年1月27日以Roivant PPS Holdings Ltd.名义注册成立的豁免有限公司。公司于2016年11月14日更名为Thalavant Sciences Ltd.并向Urovant Sciences Ltd.出售。Urovant Sciences是一家临床阶段的生物制药公司，致力于为泌尿系统疾病开发和商业化创新疗法。他们的候选产品vibegron是一种口服，每日一次的小分子，根据体外数据，是一种有效且高度选择性的β-3激动剂。Vibegron目前正在开发用于三种潜在适应症：膀胱过度活动症（OAB），良性前列腺增生或BPH男性的OAB治疗以及肠易激综合症或IBS引起的腹痛治疗。该公司的第二个候选产品URO-902是一种新型基因疗法，是该公司正在为口服药物治疗失败的OAB患者开发的一种新型基因疗法。","exchange":"NASDAQ","name":"Urovant Sciences Ltd.","nameEN":"Urovant Sciences Ltd."}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"UROV\",market:\"US\",,,undefined,":null}}